Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (2171)	3/5/2002 7:29:29 PM
From: Cacaito	Read Replies (1) \| Respond to of 2515

IRJ, you were "more" right, I was "almost" right, but the legal fight menace and Imcl need for deflection of Sec/Justice/Congress was a big part of Bmy ability to change the agreement. Nothing (yet?) in the new agreement about allowing Bmy to sell its shares at will immediately out of the 3 years lock up period. The "flat based" 39% on revnues "distribution fee" decreases the future profits of Imcl 50% or more, if Bmy goes tough it could be a bigger reduction. In general, quite good for Imcl, mediocre for Bmy. Now, it seems that Imcl could concentrate in resolving their legal problems, while Bmy concentrate on the drug: "" Bristol-Myers Squibb. ``As the world leader in oncology, we are looking forward to playing an expanded clinical and strategic role related to the ERBITUX development program, working in close collaboration with the ImClone Systems team."" I read this as Imcl will probably pay Bmy for the "expanded clinical and strategic role" (that way Bmy could recover part of its money). Maybe, not, and Bmy is just an idiot (nothing new). And the leader of the joint team is ""Andrew G. Bodnar, M.D., J.D., "" The man is a physician and LAWYER !!! I love lawyers, pillars of civilization !!!